Literature DB >> 19956559

CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells.

Silvia Deaglio1, Semra Aydin, Maurizia Mello Grand, Tiziana Vaisitti, Luciana Bergui, Giovanni D'Arena, Giovanna Chiorino, Fabio Malavasi.   

Abstract

Human CD38 is a pleiotropic glycoprotein belonging to a family of enzymes/receptors involved in the catabolism of extracellular nucleotides. CD38-receptor activities are regulated through binding to the nonsubstrate ligand CD31. CD38 expression above a critical threshold is a negative prognostic marker for chronic lymphocytic leukemia (CLL) patients. Activation of CD38 by means of agonistic monoclonal antibodies or the CD31 ligand induces proliferation and immunoblast differentiation of CLL cells. Here we define the genetic signature that follows long-term in vitro interactions between CD38(+) CLL lymphocytes and CD31(+) cells. The emerging profile confirms that the CD31/CD38 axis activates genetic programs relevant for proliferative responses. It also indicates a contribution of this pathway to the processes mediating migration and homing. These results further support the notion that the CD31/CD38 axis is part of a network of accessory signals that modify the microenvironment, favoring localization of leukemic cells to growth-permissive sites.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19956559      PMCID: PMC2785473          DOI: 10.2119/molmed.2009.00146

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  20 in total

Review 1.  Role of angiogenesis in chronic lymphocytic leukemia.

Authors:  Tomislav Letilovic; Radovan Vrhovac; Srdan Verstovsek; Branimir Jaksic; Alessandra Ferrajoli
Journal:  Cancer       Date:  2006-09-01       Impact factor: 6.860

2.  CD38/CD19: a lipid raft-dependent signaling complex in human B cells.

Authors:  Silvia Deaglio; Tiziana Vaisitti; Richard Billington; Luciana Bergui; Paola Omede'; Armando A Genazzani; Fabio Malavasi
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

3.  CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells.

Authors:  Rajendra N Damle; Sonal Temburni; Carlo Calissano; Sophia Yancopoulos; Taraneh Banapour; Cristina Sison; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2007-08-07       Impact factor: 22.113

Review 4.  Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology.

Authors:  Fabio Malavasi; Silvia Deaglio; Ada Funaro; Enza Ferrero; Alberto L Horenstein; Erika Ortolan; Tiziana Vaisitti; Semra Aydin
Journal:  Physiol Rev       Date:  2008-07       Impact factor: 37.312

5.  No convincing evidence for a role of CD31-CD38 interactions in the pathogenesis of chronic lymphocytic leukemia.

Authors:  Sanne H Tonino; Rene Spijker; Dieuwertje M P Luijks; Marinus H J van Oers; Arnon P Kater
Journal:  Blood       Date:  2008-06-02       Impact factor: 22.113

Review 6.  The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Neil E Kay
Journal:  Semin Oncol       Date:  2006-04       Impact factor: 4.929

7.  Highly purified CD38+ and CD38- sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin.

Authors:  C Pepper; R Ward; T T Lin; P Brennan; J Starczynski; M Musson; C Rowntree; P Bentley; K Mills; G Pratt; C Fegan
Journal:  Leukemia       Date:  2007-02-08       Impact factor: 11.528

8.  CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential.

Authors:  Silvia Deaglio; Tiziana Vaisitti; Semra Aydin; Luciana Bergui; Giovanni D'Arena; Lisa Bonello; Paola Omedé; Maria Scatolini; Ozren Jaksic; Giovanna Chiorino; Dimitar Efremov; Fabio Malavasi
Journal:  Blood       Date:  2007-08-15       Impact factor: 22.113

9.  CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment.

Authors:  Piers E M Patten; Andrea G S Buggins; Julie Richards; Andrew Wotherspoon; Jon Salisbury; Ghulam J Mufti; Terry J Hamblin; Stephen Devereux
Journal:  Blood       Date:  2008-03-07       Impact factor: 22.113

10.  Pathway level analysis of gene expression using singular value decomposition.

Authors:  John Tomfohr; Jun Lu; Thomas B Kepler
Journal:  BMC Bioinformatics       Date:  2005-09-12       Impact factor: 3.169

View more
  29 in total

Review 1.  Targeted Therapy in Chronic Lymphocytic Leukemia.

Authors:  Thomas J Kipps; Michael Y Choi
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

Review 2.  NAD+ metabolism and its roles in cellular processes during ageing.

Authors:  Anthony J Covarrubias; Rosalba Perrone; Alessia Grozio; Eric Verdin
Journal:  Nat Rev Mol Cell Biol       Date:  2020-12-22       Impact factor: 94.444

3.  The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting.

Authors:  T Vaisitti; V Audrito; S Serra; R Buonincontri; G Sociali; E Mannino; A Pagnani; A Zucchetto; E Tissino; C Vitale; M Coscia; C Usai; C Pepper; V Gattei; S Bruzzone; S Deaglio
Journal:  Leukemia       Date:  2014-07-03       Impact factor: 11.528

Review 4.  Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.

Authors:  Noelia Purroy; Catherine J Wu
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

5.  Effects of O-GlcNAcylation on functional mitochondrial transfer from astrocytes.

Authors:  Ji-Hyun Park; Yoshihiko Nakamura; Wenlu Li; Gen Hamanaka; Ken Arai; Eng H Lo; Kazuhide Hayakawa
Journal:  J Cereb Blood Flow Metab       Date:  2020-11-05       Impact factor: 6.200

Review 6.  CD38 and chronic lymphocytic leukemia: a decade later.

Authors:  Fabio Malavasi; Silvia Deaglio; Rajendra Damle; Giovanna Cutrona; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

7.  TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.

Authors:  Patricia K A Mongini; Rashmi Gupta; Erin Boyle; Jennifer Nieto; Hyunjoo Lee; Joanna Stein; Jela Bandovic; Tatjana Stankovic; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Charles C Chu; Nicholas Chiorazzi
Journal:  J Immunol       Date:  2015-07-01       Impact factor: 5.422

8.  CD31 Acts as a Checkpoint Molecule and Is Modulated by FcγR-Mediated Signaling in Monocytes.

Authors:  Giovanna Merchand-Reyes; Frank H Robledo-Avila; Nathaniel J Buteyn; Shalini Gautam; Ramasamy Santhanam; Kavin Fatehchand; Xiaokui Mo; Santiago Partida-Sanchez; Jonathan P Butchar; Susheela Tridandapani
Journal:  J Immunol       Date:  2019-11-15       Impact factor: 5.422

Review 9.  Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule.

Authors:  Antonella Chillemi; Gianluca Zaccarello; Valeria Quarona; Manuela Ferracin; Chiara Ghimenti; Massimo Massaia; Alberto L Horenstein; Fabio Malavasi
Journal:  Mol Med       Date:  2013-05-20       Impact factor: 6.354

Review 10.  The pathogenesis of chronic lymphocytic leukemia.

Authors:  Suping Zhang; Thomas J Kipps
Journal:  Annu Rev Pathol       Date:  2013-08-26       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.